Syntrix Receives $2.965M Grant to Conduct a Phase Ib Clinical Trial Investigating Omnitram for the Treatment of Pain in Patients Resistant to Tramadol
-Syntrix announced today the award of a $2.965 million grant from the National Institute on Drug Abuse (NIDA) of the…
Syntrix to Present at the 2016 Needham & Company 15th Annual Healthcare Conference
-Syntrix today announced that John A. Zebala, M.D., PhD, President and Chief Executive Officer, is scheduled to present at the…
Syntrix Opens Investigational New Drug (IND) Application for SX-682, a Dual CXCR1 and CXCR2 Inhibitor
-Syntrix today announced that it has opened an Investigational New Drug (IND) application with the U.S. Food and Drug Administration…
Syntrix publication in Bioorganic & Medicinal Chemistry Letters
-Congratulations to Syntrix scientists on their latest publication, which appeared in the journal Bioorganic & Medicinal Chemistry Letters. Abstract: The…
Syntrix Receives $1.725M Grant to Conduct a Phase II Clinical Trial Investigating Omnitram for the treatment of Diabetic Neuropathic Pain
-Syntrix announced today the award of a $1.725 million grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to perform a clinical study investigating the
Syntrix wins U.S. patent 8,748,623: Pyridinecarboxamides as CXCR2 modulators
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
Syntrix Publication in Bioorganic & Medicinal Chemistry Letters
-Congratulations to Syntrix scientists on their latest publication, which appeared in the journal Bioorganic & Medicinal Chemistry Letters. Abstract: Blockade of undesired neutrophil migration to sites of inflammation remains an area of substantial pharmaceutical interest….
Syntrix Wins U.S. Patent 9,000,142: Photocleavable Sense-Antisense Complex
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventor: Zebala; John…
Syntrix Wins U.S. Patent 8,993,541: Aminopyrimidine Carboxamides as CXCR2 Modulators
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
Syntrix wins U.S. patent 8,981,106: Pyrimidinecarboxamides as CXCR2 modulators
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
Syntrix wins U.S. patent 8,969,365: Thiopyrimidinecarboxamides as CXCR1/2 modulators
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
Syntrix publication in Journal of Medicinal Chemistry
-Congratulations to Syntrix scientists on their latest publication, which appeared in the ACS Journal of Medicinal Chemistry. Abstract: The G…
Syntrix wins U.S. patent 8,779,149: Aminopyridine and aminopyrimidine carboxamides as CXCR2 modulators
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
Syntrix featured in the NIH Innovation Zone at 2014 Bio International Convention in San Diego, CA
-Syntrix was selected by the NIH to host a kiosk in the Innovation Zone, an area dedicated to showcasing Small…
